208 related articles for article (PubMed ID: 14601046)
21. Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine.
Sulc M; Mrizova I; Cerna T; Frei E; Eckschlager T; Adam V; Kopeckova K; Stiborova M
Neuro Endocrinol Lett; 2016 Dec; 37(Suppl1):95-102. PubMed ID: 28263536
[TBL] [Abstract][Full Text] [Related]
22. Antitumor drug ellipticine inhibits the activities of rat hepatic cytochromes P450.
Aimová D; Stiborová M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):437-40. PubMed ID: 16601806
[TBL] [Abstract][Full Text] [Related]
23. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver.
Stiborova M; Mares J; Levova K; Pavlickova J; Barta F; Hodek P; Frei E; Schmeiser HH
Neuro Endocrinol Lett; 2011; 32 Suppl 1():121-30. PubMed ID: 22167220
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxicity of and DNA adduct formation by ellipticine and its micellar form in human leukemia cells in vitro.
Stiborova M; Manhartova Z; Hodek P; Adam V; Kizek R; Eckschlager T; Frei E
Neuro Endocrinol Lett; 2015; 36 Suppl 1():22-8. PubMed ID: 26757112
[TBL] [Abstract][Full Text] [Related]
25. Comparative 32P-postlabeling analysis of benzo[a]pyrene--DNA adducts formed in vitro upon activation of benzo[a]pyrene by human, rabbit and rodent liver microsomes.
Roggeband R; Wolterbeek AP; Rutten AA; Baan RA
Carcinogenesis; 1993 Sep; 14(9):1945-50. PubMed ID: 8403223
[TBL] [Abstract][Full Text] [Related]
26. Application of hepatic cytochrome b
Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
[TBL] [Abstract][Full Text] [Related]
27. In vivo DNA adduct formation by bisphenol A.
Atkinson A; Roy D
Environ Mol Mutagen; 1995; 26(1):60-6. PubMed ID: 7641708
[TBL] [Abstract][Full Text] [Related]
28. The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.
Stiborová M; Černá V; Moserová M; Mrízová I; Arlt VM; Frei E
Int J Mol Sci; 2014 Dec; 16(1):284-306. PubMed ID: 25547492
[TBL] [Abstract][Full Text] [Related]
29. DNA adduct formation by 7H-dibenzo[c,g]carbazole and its tissue- and organ-specific derivatives in Chinese hamster V79 cell lines stably expressing cytochrome P450 enzymes.
Gábelová A; Binková B; Valovicová Z; Srám RJ
Environ Mol Mutagen; 2004; 44(5):448-58. PubMed ID: 15534862
[TBL] [Abstract][Full Text] [Related]
30. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.
Poljaková J; Frei E; Gomez JE; Aimová D; Eckschlager T; Hrabeta J; Stiborová M
Cancer Lett; 2007 Jul; 252(2):270-9. PubMed ID: 17306925
[TBL] [Abstract][Full Text] [Related]
31. Oxidation of an antitumor drug ellipticine by peroxidases.
Poljaková J; Forsterová K; Sulc M; Frei E; Stiborová M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):449-53. PubMed ID: 16601808
[TBL] [Abstract][Full Text] [Related]
32. Formation of DNA adducts from oil-derived products analyzed by 32P-HPLC.
Akkineni LK; Zeisig M; Baranczewski P; Ekström LG; Möller L
Arch Toxicol; 2001 Jan; 74(11):720-31. PubMed ID: 11218050
[TBL] [Abstract][Full Text] [Related]
33. Identification of a genotoxic mechanism for the carcinogenicity of the environmental pollutant and suspected human carcinogen o-anisidine.
Stiborová M; Miksanová M; Sulc M; Rýdlová H; Schmeiser HH; Frei E
Int J Cancer; 2005 Sep; 116(5):667-78. PubMed ID: 15828049
[TBL] [Abstract][Full Text] [Related]
34. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2.
Stiborová M; Frei E; Wiessler M; Schmeiser HH
Chem Res Toxicol; 2001 Aug; 14(8):1128-37. PubMed ID: 11511187
[TBL] [Abstract][Full Text] [Related]
35. 32P-postlabeling analysis of benzo[a]pyrene-DNA adducts formed in vitro and in vivo.
Bodell WJ; Devanesan PD; Rogan EG; Cavalieri EL
Chem Res Toxicol; 1989; 2(5):312-5. PubMed ID: 2519823
[TBL] [Abstract][Full Text] [Related]
36. Formation, persistence, and identification of DNA adducts formed by the carcinogenic environmental pollutant o-anisidine in rats.
Naiman K; Dracínský M; Hodek P; Martínková M; Schmeiser HH; Frei E; Stiborová M
Toxicol Sci; 2012 Jun; 127(2):348-59. PubMed ID: 22403159
[TBL] [Abstract][Full Text] [Related]
37. Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells.
Indra R; Černá T; Heger Z; Hraběta J; Wilhelm M; Dostálová S; Lengálová A; Martínková M; Adam V; Eckschlager T; Schmeiser HH; Arlt VM; Stiborová M
Toxicology; 2019 May; 419():40-54. PubMed ID: 30914192
[TBL] [Abstract][Full Text] [Related]
38. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.
Stiborova M; Rupertova M; Schmeiser HH; Frei E
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2006 Jul; 150(1):13-23. PubMed ID: 16936898
[TBL] [Abstract][Full Text] [Related]
39. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer.
Stiborová M; Frei E; Hodek P; Wiessler M; Schmeiser HH
Int J Cancer; 2005 Jan; 113(2):189-97. PubMed ID: 15386410
[TBL] [Abstract][Full Text] [Related]
40. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling.
Divi RL; Osborne MR; Hewer A; Phillips DH; Poirier MC
Cancer Res; 1999 Oct; 59(19):4829-33. PubMed ID: 10519392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
